

10.00 - 11.00
ROOM B

**NOVEL SERUM MARKERS IN
HIGH-RISK PREGNANCY**



Workshop

Chair: *F. Muller (France)*

10.00 - 10.30

Quadruple testing with Inhibin A for Down's Syndrome screening on a fully automated immunoassay system
N. White (UK)

10.30 - 11.00

Two new serum tests for the prediction of preeclampsia
L. Rogers (USA)

10.00 - 11.00
ROOM L

**THE NEW cobas® 6000
ANALYZER SERIES FROM
ROCHE DIAGNOSTICS:
SETTING NEW STANDARDS IN
EFFICIENCY**



Diagnostics

Workshop

Chairs: *E. Vermeer (The Netherlands)*
H. Luthe (Germany)

10.00 - 10.30

Efficient change management in a clinical laboratory with the cobas® 6000 analyzer series
E. Vermeer (The Netherlands)

10.30 - 11.00

cobas® 6000 analyzer series -
Added value for a large - volume laboratory
H. Luthe (Germany)



Tuesday 5 June

- ISWS -

11.30 - 12.30
ROOM B

**PREECLAMPSIA, THE DISEASE
AND THE POTENTIAL FOR
EARLY DETECTION**



Workshop

Chair: I. Peoc'h (USA)

11.30 - 12.00

Clinical overview and
diagnostic/prognostic dilemmas of
preeclampsia
E.A.P. Steegers (The Netherlands)

12.00 - 12.30

Biomarkers for the early detection of
preeclampsia
R.I. Thadhani (USA)



11.30 - 12.30
ROOM L

**BIOCHIP ARRAY
TECHNOLOGY FOR RESEARCH**



Workshop

Chair: H. Skafté (Sweden)

11.30 - 11.50

S. Visvikis-Siest (France)

11.50 - 12.10

M. M. Corsi (Italy)

12.10 - 12.30

J. Lamont (UK)

13.00 - 14.00
ROOM B

**NEW TRENDS IN THE
MANAGEMENT OF CARDIAC
PATIENTS**



Workshop

Chair: F.S. Apple (USA)

13.00 - 13.10

Introduction and welcome

F.S. Apple (USA)

13.10 - 13.35

High impact of Troponin assays with superior sensitivity

P. Venge (Sweden)

13.35 - 14.00

BNP- an essential marker with high impact in the management of heart failure

C. Müller (Switzerland)

13.00 - 14.00
ROOM L

**OLYMPUS AU3000i™
IMMUNOASSAY SYSTEM**

OLYMPUS

Your Vision, Our Future

Workshop

Chair: T. Bertsch (Germany)

13.00 - 13.30

Clinical performance of the Olympus AU3000i™ Cardiac Troponin I assay

D. Gaze (UK)

13.30 - 14.00

Overall performance of the Olympus AU3000i™ Immunoassay system

A. Repáraz Andrade (Spain)



Tuesday 5 June

- ISWS -

14.30 - 15.30
ROOM B

HbA1c AND HbA2
STANDARDISATION: THE WAY
FORWARD



Workshop

Chairs: *G. John (UK)*
P. Giordano
(The Netherlands)

14.30 - 14.50
Clinical implications of HbA1c
standardisation
C. Weykamp (The Netherlands)

14.50 - 15.10
Clinical implications of HbA2
standardisation
A. Mosca (Italy)

15.10 - 15.30
Thalassemia and variant
haemoglobins: adapting laboratory
outcome to clinical practice
R. Galanello (Italy)

14.30 - 15.30
ROOM L

ADVANCED AUTOMATION
SOLUTIONS FOR HOSPITAL
LABORATORIES



Workshop

Chair:
W. W. van Solinge (The Netherlands)

14.30 - 14.45
Adding efficiency and quality to lab
services
J. Heise (Switzerland)

14.45 - 15.05
Evaluation of the new automation
system AutoMate 800
R. Dadoun (Canada)

15.05 - 15.25
First experience with AutoMate 800
in a mid-size hospital
W. F. Riesen (Switzerland)

15.25 - 15.30
Questions and discussion

16.00 - 17.00
ROOM B

**DIAGNOSTIC PERFORMANCE
AND CLINICAL VALUE OF
HOLOTRANSCOBALAMIN,
MEASURED BY THE AxSYM®
ACTIVE-B12 ASSAY, FOR
VITAMIN B12 STATUS**



Workshop

Chair: J. Scott (Ireland)

16.00 - 16.15

The use of holotranscobalamin for
vitamin B12 status in the routine
clinical setting

J. Scott (Ireland)

16.15 - 16.30

A multi-center study on the
diagnostic performance of the
holotranscobalamin assay

J. Lindemans (The Netherlands)

16.30 - 16.45

Clinical diagnosis of vitamin B12
deficiency-contribution of
holotranscobalamin

H. Schneider (Australia)

16.45 - 17.00

Clinical use and value of
holotranscobalamin determination

O. Stanger (Austria)

16.00 - 16.00
ROOM L

**NT-proBNP: AN ESSENTIAL
AND WELL ESTABLISHED
CARDIAC BIOMARKER**

DADE BEHRING

Every minute of every day™

&



Diagnostics

Workshop

Chair: J. Ordoñez (Spain)

16.00 - 16.05

Introduction

J. Ordoñez (Spain)

16.05 - 16.25

Natriuretic peptides: Analytical issues
and comparability

P. Collinson (UK)

16.25 - 16.45

Natriuretic peptides: Clinical utility
and comparability

R. van Kimmenade (The Netherlands)

16.45 - 17.00

Discussion and conclusions

Tuesday 5 June

- ISWS -